Results from oral and ocular administration of Lotemax in normal volunteers have shown that there are low or undetectable concentrations of either unchanged material or the metabolite. Results from a bioavailability study established that plasma concentrations of loteprednol etabonate following ocular administration of one drop in each eye of Lotemax eight times daily for 2 days or four times daily for 42 days were below the limit of quantitation (1 ng/mL) and detection (500 pg/mL) at all sampling times. In the same study, plasma cortisol concentrations were measured and no evidence of adrenal cortex suppression was observed. All cortisol measurements were within normal range. This study suggests that limited, if any, systemic absorption occurs with Lotemax.
Hi: This is heart breaking indeed. So, the bad news is that cataracts have begun to form, especially in one eye. The good news is that your horse still has sight out of one good eye and some sight out of the eye with the cataract. Research on Can-C reports that application of the Can-C eye drops as directed results in about 95% improvement in the subjects that were studied. Subjects have been dogs and humans – not horses – but researchers concluded that the Can-C helps reverse cataracts in all mammals including horses in, again, 95% of the cases. So, it is certainly worth a try, especially to insure that the good eye remains clear of a cataract.
% and 1% Ophthalmic Suspensions: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 2 to 4 times a day; during the initial 24 to 48 hours, may increase dosing frequency if necessary
-If signs/symptoms fail to improve after 2 days of treatment, the patient should be re-evaluated.
-Care should be taken as to not discontinue therapy prematurely.
-Anti-infective agents should me employed if a bacterial infection is present.
-Withdrawal of treatment should be carried out by gradually decreasing the frequency of applications when treating chronic conditions.
1% Ophthalmic Solution:
-Initial dose: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) up to every hour during the day and every 2 hours during the night as needed
-Maintenance dose: When a favorable response is observed, reduce dose to 1 drop every 4 hours; subsequent reduction to 1 drop 3 to 4 times a day may be adequate to control symptoms
-Duration of therapy varies depending upon the type of lesion and may extend from a few days to several weeks, based on therapeutic response.
-Relapses, which are more common in chronic active lesions than in self-limited conditions, usually respond to retreatment.
Uses: For the treatment of steroid responsive mild to moderate noninfectious allergic and inflammatory disorders of the eye (., allergic conjunctivits, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides); and for the treatment of corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies